Payment overview · 2025
General Payments
$3,182.99
40 reported records · 17 companies
Healthcare provider profile · identity verified
Gregory Gerald Smith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SACRAMENTO, CA · NPI 1952322596
Verified facts
What the public records show
CMS Open Payments records show Gregory Gerald Smith, M.D. received $3,182.99 in general payments during 2025 across 40 reported records.
Neurocrine BioSciences, Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 760 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $736.22 | 23.1% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $303.43 | 9.5% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $263.78 | 8.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $243.43 | 7.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $242.83 | 7.6% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $195.73 | 6.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $151.04 | 4.8% | 2 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $145.68 | 4.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $134.74 | 4.2% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $125.00 | 3.9% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $121.84 | 3.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $121.84 | 3.8% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $104.60 | 3.3% | 4 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $102.31 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $92.15 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $81.05 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.32 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,182.99 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $351.56 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $346.77 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $303.43 | 7 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $263.78 | 3 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $243.43 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $145.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $145.68 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $134.74 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.47 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.36 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $104.60 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $102.31 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $92.15 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $92.15 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $81.05 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $28.28 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 82 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
760 | 140 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
272 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1542 | 400 |
| Gabapentin | Gabapentin | 886 | 227 |
| Amlodipine Besylate | Amlodipine Besylate | 826 | 242 |
| Eliquis | Apixaban | 760 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 629 | 160 |
| Lisinopril | Lisinopril | 594 | 161 |
| Furosemide | Furosemide | 588 | 153 |
| Metformin Hcl | Metformin Hcl | 527 | 158 |
| Losartan Potassium | Losartan Potassium | 497 | 158 |
| Metoprolol Tartrate | Metoprolol Tartrate | 464 | 122 |
| Omeprazole | Omeprazole | 423 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 416 | 125 |
| Mirtazapine | Mirtazapine | 390 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 386 | 126 |
| Tamsulosin Hcl | Tamsulosin Hcl | 349 | 95 |
| Trazodone Hcl | Trazodone Hcl | 321 | 92 |
| Quetiapine Fumarate | Quetiapine Fumarate | 313 | 79 |
| Famotidine | Famotidine | 296 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 285 | 80 |
| Potassium Chloride | Potassium Chloride | 281 | 72 |
| Baclofen | Baclofen | 272 | 70 |
| Jardiance | Empagliflozin | 272 | 65 |
| Carvedilol | Carvedilol | 266 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 240 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 235 | 100 |
| Levetiracetam | Levetiracetam | 217 | 56 |
| Donepezil Hcl | Donepezil Hcl | 213 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 210 | 59 |
| Simvastatin | Simvastatin | 202 | 53 |
| Sertraline Hcl | Sertraline Hcl | 199 | 44 |
| Divalproex Sodium | Divalproex Sodium | 198 | 49 |
| Xarelto | Rivaroxaban | 186 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 49 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 163 | 69 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 161 | 56 |
| Olanzapine | Olanzapine | 151 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 47 |
| Spironolactone | Spironolactone | 146 | 45 |
| Januvia | Sitagliptin Phosphate | 140 | 28 |
| Montelukast Sodium | Montelukast Sodium | 140 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 136 | 54 |
| Meloxicam | Meloxicam | 132 | 34 |
| Risperidone | Risperidone | 132 | 24 |
| Allopurinol | Allopurinol | 131 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 130 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 38 |
| Metformin Hcl Er | Metformin Hcl | 126 | 39 |
| Albuterol Sulfate | Albuterol Sulfate | 118 | 36 |
| Glipizide | Glipizide | 118 | 32 |
| Lactulose | Lactulose | 110 | 35 |
| Buspirone Hcl | Buspirone Hcl | 99 | 25 |
| Lidocaine | Lidocaine | 99 | 26 |
| Warfarin Sodium | Warfarin Sodium | 97 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 95 | 23 |
| Alendronate Sodium | Alendronate Sodium | 94 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 29 |
| Ibuprofen | Ibuprofen | 93 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 40 |
| Bumetanide | Bumetanide | 90 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 89 | 22 |
| Midodrine Hcl | Midodrine Hcl | 86 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 84 | 46 |
| Farxiga | Dapagliflozin Propanediol | 82 | 12 |
| Lorazepam | Lorazepam | 82 | 39 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 21 |
| Memantine Hcl | Memantine Hcl | 80 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 28 |
| Finasteride | Finasteride | 78 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 78 | 28 |
| Latanoprost | Latanoprost | 78 | 18 |
| Prednisone | Prednisone | 75 | 38 |
| Topiramate | Topiramate | 73 | suppressed |
| Celecoxib | Celecoxib | 71 | 18 |
| Atenolol | Atenolol | 69 | 18 |
| Myrbetriq | Mirabegron | 69 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 66 | 21 |
| Glimepiride | Glimepiride | 65 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 13 |
| Nystatin | Nystatin | 62 | 34 |
| Nystop | Nystatin | 60 | 33 |
| Azelastine Hcl | Azelastine Hcl | 59 | 25 |
| Cephalexin | Cephalexin | 59 | 48 |
| Tramadol Hcl | Tramadol Hcl | 59 | 27 |
| Valsartan | Valsartan | 59 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 12 |
| Naproxen | Naproxen | 57 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 14 |
| Glycopyrrolate | Glycopyrrolate | 56 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 55 | 22 |
| Sucralfate | Sucralfate | 55 | 13 |
| Glipizide Er | Glipizide | 54 | 14 |
| Linzess | Linaclotide | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 14 |
| Nifedipine Er | Nifedipine | 54 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | 12 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 52 | 15 |
| Aripiprazole | Aripiprazole | 51 | 17 |
| Brilinta | Ticagrelor | 51 | suppressed |
| Digoxin | Digoxin | 51 | 17 |
| Azithromycin | Azithromycin | 49 | 37 |
| Scopolamine | Scopolamine | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | 14 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | 19 |
| Ondansetron Odt | Ondansetron | 45 | 18 |
| Insulin Aspart Flexpen | Insulin Aspart | 44 | 19 |
| Lovastatin | Lovastatin | 44 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Insulin Lispro | Insulin Lispro | 43 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 11 |
| Pregabalin | Pregabalin | 43 | 16 |
| Budesonide | Budesonide | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 41 | 11 |
| Bupropion Hcl | Bupropion Hcl | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 18 |
| Rybelsus | Semaglutide | 39 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 11 |
| Ezetimibe | Ezetimibe | 37 | 15 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 37 | suppressed |
| Humalog | Insulin Lispro | 36 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Ozempic | Semaglutide | 35 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 32 | 15 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 31 | 11 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 23 |
| Movantik | Naloxegol Oxalate | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 20 |
| Anastrozole | Anastrozole | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 29 | 11 |
| Morphine Sulfate | Morphine Sulfate | 29 | 18 |
| Nurtec Odt | Rimegepant Sulfate | 29 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | 11 |
| Permethrin | Permethrin | 28 | 18 |
| Xifaxan | Rifaximin | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 26 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 25 | suppressed |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Ivermectin | Ivermectin | 22 | 16 |
| Ketoconazole | Ketoconazole | 22 | 13 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Enulose | Lactulose | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Phenytoin | Phenytoin | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Hydrocortisone | Hydrocortisone | 19 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Olanzapine Odt | Olanzapine | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | 14 |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Xtampza Er | Oxycodone Myristate | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Penicillin G Potassium | Penicillin G Potassium | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Risperidone Odt | Risperidone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tacrolimus | Tacrolimus | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Alvesco | Ciclesonide | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Drizalma Sprinkle | Duloxetine Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nafcillin Sodium | Nafcillin Sodium | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Toprol Xl | Metoprolol Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,182.99 · 40 records | Neurocrine BioSciences, Inc. | AUSTEDO XR, BREZTRI, CAPLYTA, COBENFY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, DUPIXENT, EPIDIOLEX, FANAPT, FARXIGA, Fintepla, HETLIOZ, INGREZZA, KISUNLA, Kerecis GraftGuide, Kerecis SurgiClose, Kerendia, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error